Biointron’s AbDrop™ Platform: Revolutionizing Screening

Microfluidic Technology for Efficient Antibody Screening

The AbDrop™ platform uses microfluidic technology to encapsulate individual plasma cells in droplets. Built on single B cell antibody technologies, the platform combines high-throughput screening, next-generation sequencing, and target assessment to streamline the antibody drug discovery process, accelerate antibody identification, and support the discovery of therapeutic antibodies. This high-throughput approach enables researchers to screen millions of plasma B cells in a single day, accelerating antibody screen workflows while preserving naturally paired heavy and light chains for downstream antibody discovery, therapeutic antibodies, and drug development.

Antibody Screening Workflow Highlights:

• One Day: Millions of B cells screened for antibody-producing potential. 

• One Week: High-throughput sequencing and data analysis. 

• One Month: Purified antibodies with validated activity. 

• One Screening Cycle: Hundreds of naturally paired heavy and light chains obtained. 

High-throughput screening combined with gene fragments analysis and next generation sequencing enables rapid antibody identification, improves antibody specificity, and supports efficient target assessment for promising antibody candidates.

This platform reduces reagent consumption, integrates multiple development steps, and increases precision. Researchers can identify unique and functional antibodies faster, ensuring the discovery of effective therapeutic candidates, while supporting antibody discovery, antibody specificity, and the selection of optimal target antigen candidates for drug development.

Fully Human Antibody Models for Advanced Antibody Screening

HUGO-Ab™ Mice for High-Quality Therapeutic Antibodies

The HUGO-Ab™ mice are genetically engineered to produce fully human antibodies. Using proprietary TurboKnockout® ES technology, these mice achieve stable phenotypic and functional outcomes without requiring humanization steps. These fully human antibody models support the generation of IgG antibodies for therapeutic antibodies and complement workflows based on phage display, while avoiding many limitations associated with conventional phage display approaches.

Advantages of HUGO-Ab™ Mice:

• High Affinity and Low Immunogenicity: Antibodies derived from these mice exhibit strong target binding and minimal immune response, critical for safety and efficacy. 

• Proven Performance: Recognized by leading institutions, HUGO-Ab™ mice have consistently delivered high-quality therapeutic antibodies. 

• Enhanced Diversity: These mice include the full spectrum of human antibody heavy and light chain genes, increasing the diversity of potential antibody candidates. 

• The resulting antibodies are suitable for downstream characterization using flow cytometry, enzyme-linked immunosorbent assay, and other analytical methods to confirm antibody specificity and target binding.

Integrated Antibody Screening and Fully Human Antibody Discovery

Our High-throughput Fully Human Antibody Discovery Platform integrates Cyagen’s HUGO-Ab™ mice with Biointron’s AbDrop™ microdroplet-based single B cell screening. This powerful combination enhances antibody screening by accelerating the discovery and development of fully human antibodies, reducing the time from target identification to therapeutic candidate to just three months. Learn more about the service here.